Denosumab prevents acetabular bone loss around an uncemented cup: analysis of secondary outcomes in a randomized controlled trial.

Background and purpose -- Uncemented total hip arthroplasty (THA) is associated with periprosthetic bone loss. In a secondary outcome analysis from a randomized controlled trial, we studied whether denosumab can prevent loss of acetabular periprosthetic bone mineral density (pBMD) in patients who re...

Descripción completa

Detalles Bibliográficos
Publicado en:Acta Orthopaedica Vol. 93; pp. 708 - 720
Autores principales: KIRITOPOULOS, Demostenis, NYSTRÖM, Andreas, ULLMARK, Gösta, SÖRENSEN, Jens, PETRÉN-MALLMIN, Marianne, MILBRINK, Jan, HAILER, Nils P., MALLMIN, Hans
Formato: diagnostic images research tables/charts randomized controlled trial Journal Article
Publicado: Medical Journals Sweden AB 2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=162614259&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 162614259
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        17453674
        1BVL
      jtl: Acta Orthopaedica
      issn: 17453674
      maglogo: N
    pubinfo:
      dt: 2022
      vid: 93
      pid: 59195
      pub: Medical Journals Sweden AB
    artinfo:
      ui:
        162614259
        162614259
        162614259
        10.2340/17453674.2022.4537
        162614259
      ppf: 708
      ppct: 12
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Denosumab prevents acetabular bone loss around an uncemented cup: analysis of secondary outcomes in a randomized controlled trial.
      aug:
        au:
          KIRITOPOULOS, Demostenis
          NYSTRÖM, Andreas
          ULLMARK, Gösta
          SÖRENSEN, Jens
          PETRÉN-MALLMIN, Marianne
          MILBRINK, Jan
          HAILER, Nils P.
          MALLMIN, Hans
        affil: Department of Surgical Sciences/Section of Orthopedics, Uppsala University
      sug:
        subj:
          Antibodies, Monoclonal Therapeutic Use
          Bone Cements
          Acetabulum Pathology
          Bone Diseases
          Human
          Randomized Controlled Trials
          Random Assignment
          Adult
          Middle Age
          Aged
          Biological Markers
          Osteoarthritis, Hip
          Absorptiometry, Photon Methods
          Exploratory Research
          Bone Resorption
          Bone Density
          Positron-Emission Tomography
          Tomography, X-Ray Computed
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
      ab: Background and purpose -- Uncemented total hip arthroplasty (THA) is associated with periprosthetic bone loss. In a secondary outcome analysis from a randomized controlled trial, we studied whether denosumab can prevent loss of acetabular periprosthetic bone mineral density (pBMD) in patients who received a trabecular metal cup during uncemented THA. Patients and methods -- 64 patients (aged 35--65 years) with unilateral osteoarthritis of the hip were randomized to 2 subcutaneous injections with denosumab or placebo, given 1--3 days post-surgery and 6 months post-surgery. Acetabular pBMD was measured in 5 regions of interest (ROIs) by dual-energy X-ray absorptiometry. Serum markers for bone metabolism were analyzed. Periprosthetic osteoblastic activity, measured as standardized uptake values (SUVs) by [18F] positron emission tomography/computed tomography, was evaluated in 32 of the 64 study patients. Results -- After 12 months, patients treated with denosumab had higher pBMD compared with the placebo-treated patients in 4 of 5 ROIs and in sum of ROIs 1--5. After 24 months, the effect on pBMD for patients treated with denosumab declined. Serum markers declined pronouncedly up to 12 months in patients treated with denosumab, but rebounded above baseline levels after 24 months. Patients treated with denosumab had statistically significantly lower SUVs in all ROIs, except ROI 5, after 6 months. Interpretation -- Based on this exploratory analysis of secondary endpoints the application of denosumab seems associated with preserved acetabular pBMD, reduced bone metabolism and attenuated periprosthetic osteoblastic activity. However, given the known rebound affects after discontinuation of denosumab treatment, these effects cannot be expected to persist. If prolonged treatment or shift to other regimes would be beneficial to reduce the risk of cup loosening is yet to be investigated.
      pubtype: Academic Journal
      doctype:
        diagnostic images
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N